Article
[Inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase: similarity and differences].
Revue de pneumologie clinique - 1 Jun 2011
Lokiec F, Douillard J-Y
Abstract excerpt
Tyrosine kinase inhibitors (TKI) of EGFR are used in advanced non-small cell lung cancer (NSCLC) in 2(nd) and 3(rd) line, and for gefitinib in first line in case of EGFR mutations. These drugs are particularly active in presence of these mutations, with response rate around 60-70%. Pharmacologica...
Topics
- Animals
- Antineoplastic Combined Chemotherapy Protocols
- Biomarkers, Tumor
- Carcinoma, Non-Small-Cell Lung
- Clinical Trials, Phase II as Topic
- ErbB Receptors
- Erlotinib Hydrochloride
- Evidence-Based Medicine
- Gefitinib
- Genes, erbB-1
- Humans
- Lung Neoplasms
- Mutation
- Neoplasm Staging
- Odds Ratio
- Protein Kinase Inhibitors
- Quinazolines
- Survival Analysis